BIGBEAR
PHARMACEUTICALS
Brain Metastasis Buster.
Drug-Resistant Mutation Terminator.
AuthenticGuaranteeFast DeliveryPrivacy On November 2, 2018, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved lorlatinib, a third-generation anaplastic lymphoma···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 71
On March 3, 2021, the U.S. Food and Drug Administration (FDA) approved Pfizer's supplemental New Drug Application (sNDA) for lorlatinib, expanding···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 71
Copyright2024@ BIGBEAR All right reserved BIGBEAR
